Epidemiological Characteristics and 3-year Overall Survival Outcome of Nasopharyngeal Cancer in Central Java: A Single Institution Retrospective Study

Rikha Liemiyah, Dian Ayu Ruspita, Zulfikar Naftali, Muyassaroh Muyassaroh, Farokah Farokah


Background: Nasopharyngeal cancer (NPC) has a high incidence and mortality rate in Indonesia, indicating poor survival outcomes. We aimed to evaluate the survival rate of NPC patients and the influence of specific underlying epidemiological characteristics on the overall survival (OS) rate of NPC patients.


Methods: We reviewed the medical data from Dr. Kariadi General Hospital's clinical registry system for all newly diagnosed NPC patients between January and December 2018. We retrieved NPC patients' medical record data that met our inclusion/exclusion criteria. The overall survival rate (OS) was estimated using the Kaplan-Meier method. Between-group stratified three-year OS comparisons were conducted using weighted log-rank tests. All statistical analysis was performed in R statistical software.


Results: A total of 50  NPC patients were included in the study. Majority of NPC patients were diagnosed in younger age group (58.0%). Male NPC patients dominated this study (74.0%). NPC patients were mostly diagnosed at the advanced stage (76.0%). Nonkeratinizing histology types were frequently found in the study (82.0%). NPC patients achieved a desirable better performance status (78.0%) and had no comorbidities (74.0%). Most NPC patients demonstrated a complete response to therapy (58.0%). The mean follow-up was 26.36 ± 9.5 months and drop-out rate was 18.0%. The three-year OS was 60.8%. Age, sex, stage, histological classification, performance status, comorbidity, therapy response, and therapy drop-out stratified OS did not statistically differ among NPC patients.


Conclusions: We found a satisfactory NPC three-year OS. The underlying epidemiological characteristics did not significantly influence the NPC patients' three-year OS.


Central Java, nasopharyngeal cancer, survival rate

Full Text: View | Download

DOI: 10.33371/ijoc.v18i2.1083

Article Metrics

Abstract View: 110,
PDF Download: 37


Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, et al. Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia. Osong Public Heal Res Perspect 2016; 7: 360–372.

Wong KCW, Hui EP, Lo K-W, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 2021; 18: 679–695.

The Global Cancer Observatory. Cancer Population Fact Sheet - Indonesia, https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf (2020).

Eberth JM, Zahnd WE, Adams SA, et al. Mortality-to-incidence ratios by US Congressional District: Implications for epidemiologic, dissemination and implementation research, and public health policy. Prev Med (Baltim) 2019; 129: 105849.

Adham M, Mat Lazim N, Carlos R. Clinical presentation of nasopharyngeal carcinoma. In: Abdullah B, Balasubramanian A, Mat Lazim N (eds) An Evidence-Based Approach to the Management of Nasopharyngeal Cancer: From Basic Science to Clinical Presentation and Treatment. Cambridge, MA: Academic Press, 2020, pp. 93–109.

Mariotto AB, Noone A-M, Howlader N, et al. Cancer Survival: An Overview of Measures, Uses, and Interpretation. JNCI Monogr 2014; 2014: 145–186.

Galvin A, Delva F, Helmer C, et al. Sociodemographic, socioeconomic, and clinical determinants of survival in patients with cancer: A systematic review of the literature focused on the elderly. J Geriatr Oncol 2018; 9: 6–14.

Toporcov TN, Filho VW. Epidemiological science and cancer control. Clinics 2018; 73: e627s.

Patel VJ, Chen N-W, Resto VA. Racial and Ethnic Disparities in Nasopharyngeal Cancer Survival in the United States: A SEER Study. Otolaryngol Neck Surg 2017; 156: 122–131.

Cao S-M, Simons MJ, Qian C-N. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 2011; 30: 114–119.

Mahendradhata Y, Trisnantoro L, Listyadewi S, et al. The Republic of Indonesia health system review. 2017.

Richiardi L, Pizzi C, Pearce N. Commentary: Representativeness is usually not necessary and often should be avoided. Int J Epidemiol 2013; 42: 1018–1022.

Adham M, Kurniawan AN, Muhtadi AI, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer 2012; 31: 185–196.

Sekarutami SM, Gondhowiardjo S, Yuliasti R, et al. Survival of nasopharyngeal cancer in national referral hospital of Indonesia: A study on radiotherapy patients. Oral Oncol 2020; 106: 104707.

Sun X, Tong L-P, Wang Y-T, et al. Can Global Variation of Nasopharynx Cancer Be Retrieved from the Combined Analyses of IARC Cancer Information (CIN) Databases? PLoS One 2011; 6: e22039.

Schmid E. Ethnic Groups in Indonesia: The Javanese. Munich: GRIN Verlag, 2015.

Hess KR. Cancer survival analysis. In: Amin MB, Edge SB, Greene FL, et al. (eds) AJCC Cancer Staging Manual. Chicago, IL: Springer Cham, 2017, pp. 39–45.

Banerjee M, Lao CD, Wancata LM, et al. Implications of age and conditional survival estimates for patients with melanoma. Melanoma Res 2016; 26: 77–82.

Deliana M, Suza DE, Tarigan R. Advanced Stage Cancer Patients Experience in Seeking Treatment in Medan, Indonesia. Open access Maced J Med Sci 2019; 7: 2194–2203.

Lee AW, Lydiatt WM, Colevas AD, et al. Nasopharynx. In: Amin MB, Edge SB, Greene FL, et al. (eds) AJCC Cancer Staging Manual. Chicago, IL: Springer Cham, 2017, pp. 103–111.

Vitzthum LK, Feng CH, Noticewala S, et al. Comparison of Comorbidity and Frailty Indices in Patients With Head and Neck Cancer Using an Online Tool. JCO Clin cancer informatics 2018; 2: 1–9.

Azam F, Latif MF, Farooq A, et al. Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. Case Rep Oncol 2019; 12: 728–736.

Nishino M. Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond. Am Soc Clin Oncol Educ B 2018; 38: 1019–1029.

Prinja S, Gupta N, Verma R. Censoring in clinical trials: review of survival analysis techniques. Indian J community Med 2010; 35: 217–221.

Komiter Penanggulangan Kanker Nasional. Panduan penatalaksanaan kanker nasofaring. Jakarta, 2019.

Machin D, Campbell MJ, Tan SB, et al. Comparing survival curve. In: Machin D, Campbell MJ, Tan SB, et al. (eds) Sample size tables for clinial studies. Hoboken, NJ: Wiley Blackwell, 2009, pp. 84–101.

Avdulla CS, Papadas T, Mastronikolis N, et al. Epidemiological Characteristics and Survival Analysis of Patients With Nasopharyngeal Cancer in Western Greece. Cureus 2021; 13: e14711.

R Core Team. R: A Language and Environment for Statistical Computing, https://www.r-project.org/ (2023).

Therneau TM. A Package for Survival Analysis in R, https://cran.r-project.org/package=survival (2023).

Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer, 2000.

Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using ‘ggplot2’, https://cran.r-project.org/package=survminer (2021).

Karrison TG. Versatile Tests for Comparing Survival Curves Based on Weighted Log-rank Statistics. Stata J 2016; 16: 678–690.

Bouliotis G, Billingham L. Crossing survival curves: alternatives to the log-rank test. Trials 2011; 12: A137.

Kleinbaum DG, Klein M. Kaplan-Meier survival curve and the log-rank test. In: Gail M, Krickeberg K, Samet J, et al. (eds) Survival analysis: A self-learning text. New York, NY: Springer, 2011, pp. 55–96.

Schober P, Vetter TR. Survival Analysis and Interpretation of Time-to-Event Data: The Tortoise and the Hare. Anesth Analg 2018; 127: 792–798.

Reffai A, Mesmoudi M, Derkaoui T, et al. Epidemiological Profile and Clinicopathological, Therapeutic, and Prognostic Characteristics of Nasopharyngeal Carcinoma in Northern Morocco. Cancer Control 2021; 28: 1–12.

Hutajulu SH, Howdon D, Taroeno-Hariadi KW, et al. Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta, Indonesia: A hospital-based retrospective study. PLoS One 2021; 16: e0246638.

Beca JM, Chan KKW, Naimark DMJ, et al. Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study. BMC Med Res Methodol 2021; 21: 282.

Liu B, Zhang M, Cao Y, et al. A nonendemic analysis of the patterns and prognosis of de novo metastatic nasopharyngeal carcinomas in older patients aged ≥ 65 years. Sci Rep 2022; 12: 8321.

Zhu Y, Song X, Li R, et al. Assessment of Nasopharyngeal Cancer in Young Patients Aged ≤ 30 Years. Front Oncol 2019; 9: 1179.

Klein CA. Cancer progression and the invisible phase of metastatic colonization. Nat Rev Cancer 2020; 20: 681–694.

Chakraborty S, Rahman T. The difficulties in cancer treatment. Ecancermedicalscience 2012; 6: ed16.

Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 2018; 15: 81–94.

Shen S, Vagner S, Robert C. Persistent Cancer Cells: The Deadly Survivors. Cell 2020; 183: 860–874.

Cone EB, Marchese M, Paciotti M, et al. Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. JAMA Netw open 2020; 3: e2030072.

Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 2020; 371: m4087.

Ou S-HI, Zell JA, Ziogas A, et al. Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann Oncol Off J Eur Soc Med Oncol 2007; 18: 29–35.

Cooper T, Biron VL, Adam B, et al. Association of Keratinization With 5-Year Disease-Specific Survival in Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngol Neck Surg 2015; 141: 250–256.

Wu S-G, Lian C-L, Wang J, et al. The effect of histological subtypes on survival outcome in nasopharyngeal carcinoma after extensive follow up. Ann Transl Med 2019; 7: 768.

Minhinnick A, Aye PS, Elwood JM, et al. Cancer of the nasopharynx in Aotearoa New Zealand from 1994 to 2018: Incidence and survival in a population-based, national registry cohort study. Lancet Reg Heal West Pacific 2022; 24: 100522.

Gao W, Li JZ, Ho WK, et al. Biomarkers for Use in Monitoring Responses of Nasopharyngeal Carcinoma Cells to Ionizing Radiation. Sensors 2012; 12: 8832–8846.

Broccolo F, Ciccarese G, Rossi A, et al. Human papillomavirus (HPV) and Epstein-Barr virus (EBV) in keratinizing versus non- keratinizing squamous cell carcinoma of the oropharynx. Infect Agent Cancer 2018; 13: 32.

Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 2011; 30: 127–138.

Chen W, Hu G-H. Biomarkers for enhancing the radiosensitivity of nasopharyngeal carcinoma. Cancer Biol Med 2015; 12: 23–32.

Jögi A, Vaapil M, Johansson M, et al. Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors. Ups J Med Sci 2012; 117: 217–224.

Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013; 501: 328–337.

Dwijayanti F, Prabawa A, Besral, et al. The Five-Year Survival Rate of Patients with Nasopharyngeal Carcinoma Based on Tumor Response after Receiving Neoadjuvant Chemotherapy, Followed by Chemoradiation, in Indonesia: A Retrospective Study. Oncology 2020; 98: 154–160.

Korkmaz M, Eryılmaz MK, Koçak MZ, et al. The goal of primary therapy in non-metastatic nasopharyngeal cancer should be radiological complete response. Egypt J Otolaryngol 2022; 38: 79.

Lüönd F, Tiede S, Christofori G. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer 2021; 125: 164–175.

Sun X, Yu Q. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacol Sin 2015; 36: 1219–1227.

Tilsed CM, Fisher SA, Nowak AK, et al. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol 2022; 12: 960317.

Palmer AC, Sorger PK. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell 2017; 171: 1678-1691.e13.

Lim Z-F, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol 2019; 12: 134.

Kennedy SR, Loeb LA, Herr AJ. Somatic mutations in aging, cancer and neurodegeneration. Mech Ageing Dev 2012; 133: 118–126.

Stead ER, Bjedov I. Balancing DNA repair to prevent ageing and cancer. Exp Cell Res 2021; 405: 112679.

Baskar R, Dai J, Wenlong N, et al. Biological response of cancer cells to radiation treatment. Front Mol Biosci 2014; 1: 24.

Gerber DE. Performance Status–Based Oncology Practice Guidelines: Easier Said Than Done. J Oncol Pract 2016; 12: 597–599.

Scott JM, Stene G, Edvardsen E, et al. Performance Status in Cancer: Not Broken, But Time for an Upgrade? J Clin Oncol 2020; 38: 2824–2829.

Fangzheng W, Chuner J, Haiyan Q, et al. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area. Medicine (Baltimore) 2019; 98: e18484.

Huang Y, Chen W, Haque W, et al. The impact of comorbidity on overall survival in elderly nasopharyngeal carcinoma patients: a National Cancer Data Base analysis. Cancer Med 2018; 7: 1093–1101.

Li W-Z, Lv S-H, Liu G-Y, et al. Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival. Biol Sex Differ 2021; 12: 18.

Rubin JB, Lagas JS, Broestl L, et al. Sex differences in cancer mechanisms. Biol Sex Differ 2020; 11: 17.

Rana RH, Alam F, Alam K, et al. Gender-specific differences in care-seeking behaviour among lung cancer patients: a systematic review. J Cancer Res Clin Oncol 2020; 146: 1169–1196.

Burnside C, Hudson T, Williams C, et al. Sex differences in the use of healthcare services among US adults with and without a cancer diagnosis. Turkish J Urol 2018; 44: 298–302.

Wang F, Jiang C, Qin H, et al. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area. Medicine (Baltimore) 2019; 98: e18484.

Huang R-D, Sun Z, Wang X-H, et al. Development of a Comorbidity-Based Nomogram to Predict Survival After Salvage Reirradiation of Locally Recurrent Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era. Front Oncol; 10.

Fowler H, Belot A, Ellis L, et al. Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers. BMC Cancer 2020; 20: 2.

Panigrahi G, Ambs S. How Comorbidities Shape Cancer Biology and Survival. Trends in cancer 2021; 7: 488–495.

Alshamsan B, Gad AM, Alata MK, et al. Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer. J Oncol 2022; 2022: 6860413.

West H (Jack), Jin JO. Performance Status in Patients With Cancer. JAMA Oncol 2015; 1: 998.

Prigerson HG, Bao Y, Shah MA, et al. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol 2015; 1: 778–784.

Sehgal K, Gill RR, Widick P, et al. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Netw open 2021; 4: e2037120.

Xu C, Yang K-B, Feng R-J, et al. Radiotherapy interruption due to holidays adversely affects the survival of patients with nasopharyngeal carcinoma: a joint analysis based on large-scale retrospective data and clinical trials. Radiat Oncol 2022; 17: 36.

Yao J-J, Jin Y-N, Wang S-Y, et al. The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis. BMC Cancer 2018; 18: 740.

Dharmarajan K V, Presley CJ, Wyld L. Care Disparities Across the Health Care Continuum for Older Adults: Lessons From Multidisciplinary Perspectives. Am Soc Clin Oncol Educ B 2021; 41: e215–e224.

Jager KJ, Tripepi G, Chesnaye NC, et al. Where to look for the most frequent biases? Nephrology (Carlton) 2020; 25: 435–441.

Bishop DVM, Thompson J, Parker AJ. Can we shift belief in the ‘Law of Small Numbers’? R Soc Open Sci 2022; 9: 211028.

Hazra A, Gogtay N. Biostatistics Series Module 9: Survival Analysis. Indian J Dermatol 2017; 62: 251–257.

Wang Z, Zhang A, Chen Y, et al. Type I error inflation of log-rank test with small sample size. J Stat Res 2019; 53: 93–109.

Netz Y, Lidor R, Ziv G. Small samples and increased variability – discussing the need for restricted types of randomization in exercise interventions in old age. Eur Rev Aging Phys Act 2019; 16: 17.

Le-Rademacher J, Wang X. Time-To-Event Data: An Overview and Analysis Considerations. J Thorac Oncol 2021; 16: 1067–1074.

Button KS, Ioannidis JPA, Mokrysz C, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013; 14: 365–376.

Gebski V, Garès V, Gibbs E, et al. Data maturity and follow-up in time-to-event analyses. Int J Epidemiol 2018; 47: 850–859.


  • There are currently no refbacks.

Copyright (c) 2024 Rikha Liemiyah

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.